Biological markers of Alzheimer's disease in cerebrospinal fluid: clinical and laboratory comparisons
Diagnostic hypothesis of Alzheimer's disease (AD) is based on the typical clinical picture of the disease and the exclusion of other diseases manifesting by cognitive and behavioural disorders by MRI scans of the brain and laboratory tests. For an accurate diagnosis of AD and exclusion of other...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2024-06-01
|
| Series: | Неврология, нейропсихиатрия, психосоматика |
| Subjects: | |
| Online Access: | https://nnp.ima-press.net/nnp/article/view/2279 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850186710550315008 |
|---|---|
| author | K. V. Shevtsova D. O. Rozhkov D. A. Grishina V. V. Grinyuk V. V. Zakharov N. M. Kashakanova N. N. Koberskaya O. V. Kosivtsova A. B. Lokshina Yu. A. Starchina A. Yu. Tyurina A. Yu. Fedorova V. A. Parfenov |
| author_facet | K. V. Shevtsova D. O. Rozhkov D. A. Grishina V. V. Grinyuk V. V. Zakharov N. M. Kashakanova N. N. Koberskaya O. V. Kosivtsova A. B. Lokshina Yu. A. Starchina A. Yu. Tyurina A. Yu. Fedorova V. A. Parfenov |
| author_sort | K. V. Shevtsova |
| collection | DOAJ |
| description | Diagnostic hypothesis of Alzheimer's disease (AD) is based on the typical clinical picture of the disease and the exclusion of other diseases manifesting by cognitive and behavioural disorders by MRI scans of the brain and laboratory tests. For an accurate diagnosis of AD and exclusion of other diseases, detection of biological markers (biomarkers) of AD in the cerebrospinal fluid (CSF) is of great importance: a decrease in the level of beta-amyloid (Ав^ -42) and an increase in the level of phosphorylated tau protein. The analysis of AD biomarkers in the CSF of 63 patients (16 men and 47 women, mean age 72±8.7 years) with a typical picture of AD [30 patients in the moderate cognitive impairment (MCI) stage and 33 in the mild dementia stage] allowed us to confirm the diagnosis in 54 cases (85.3%) and to exclude it in the remaining nine patients (14.7%). We present a case of a 59-year-old patient with MCI in whom biomarkers typical of AD were detected in the CSF, confirming the diagnosis of AD. We also present the observations of two patients with possible AD, in whom the results of the CSF examination made it possible to rule out AD and indicated hippocampal sclerosis and tauopathy. At present, an accurate diagnosis of AD based on the study of biomarkers of the disease is of great practical importance, since at the stage of MCI and mild dementia it is possible to prevent the progression of AD with anti-amyloid therapy. Currently, AD is rarely diagnosed in our country, so it is of great importance to inform physicians about modern methods of diagnosis and treatment of AD. |
| format | Article |
| id | doaj-art-e2c829d74d8040be9b16c28d1cf68c80 |
| institution | OA Journals |
| issn | 2074-2711 2310-1342 |
| language | Russian |
| publishDate | 2024-06-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Неврология, нейропсихиатрия, психосоматика |
| spelling | doaj-art-e2c829d74d8040be9b16c28d1cf68c802025-08-20T02:16:17ZrusIMA-PRESS LLCНеврология, нейропсихиатрия, психосоматика2074-27112310-13422024-06-011639610210.14412/2074-2711-2024-3-96-1021496Biological markers of Alzheimer's disease in cerebrospinal fluid: clinical and laboratory comparisonsK. V. Shevtsova0D. O. Rozhkov1D. A. Grishina2V. V. Grinyuk3V. V. Zakharov4N. M. Kashakanova5N. N. Koberskaya6O. V. Kosivtsova7A. B. Lokshina8Yu. A. Starchina9A. Yu. Tyurina10A. Yu. Fedorova11V. A. Parfenov12A.Ya. Kozhevnikov Clinic of Nervous System Diseases, Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)A.Ya. Kozhevnikov Clinic of Nervous System Diseases, Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)A.Ya. Kozhevnikov Clinic of Nervous System Diseases, Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)A.Ya. Kozhevnikov Clinic of Nervous System Diseases, Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)A.Ya. Kozhevnikov Clinic of Nervous System Diseases, Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)A.Ya. Kozhevnikov Clinic of Nervous System Diseases, Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)A.Ya. Kozhevnikov Clinic of Nervous System Diseases, Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)A.Ya. Kozhevnikov Clinic of Nervous System Diseases, Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)A.Ya. Kozhevnikov Clinic of Nervous System Diseases, Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)A.Ya. Kozhevnikov Clinic of Nervous System Diseases, Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)A.Ya. Kozhevnikov Clinic of Nervous System Diseases, Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)A.Ya. Kozhevnikov Clinic of Nervous System Diseases, Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)A.Ya. Kozhevnikov Clinic of Nervous System Diseases, Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)Diagnostic hypothesis of Alzheimer's disease (AD) is based on the typical clinical picture of the disease and the exclusion of other diseases manifesting by cognitive and behavioural disorders by MRI scans of the brain and laboratory tests. For an accurate diagnosis of AD and exclusion of other diseases, detection of biological markers (biomarkers) of AD in the cerebrospinal fluid (CSF) is of great importance: a decrease in the level of beta-amyloid (Ав^ -42) and an increase in the level of phosphorylated tau protein. The analysis of AD biomarkers in the CSF of 63 patients (16 men and 47 women, mean age 72±8.7 years) with a typical picture of AD [30 patients in the moderate cognitive impairment (MCI) stage and 33 in the mild dementia stage] allowed us to confirm the diagnosis in 54 cases (85.3%) and to exclude it in the remaining nine patients (14.7%). We present a case of a 59-year-old patient with MCI in whom biomarkers typical of AD were detected in the CSF, confirming the diagnosis of AD. We also present the observations of two patients with possible AD, in whom the results of the CSF examination made it possible to rule out AD and indicated hippocampal sclerosis and tauopathy. At present, an accurate diagnosis of AD based on the study of biomarkers of the disease is of great practical importance, since at the stage of MCI and mild dementia it is possible to prevent the progression of AD with anti-amyloid therapy. Currently, AD is rarely diagnosed in our country, so it is of great importance to inform physicians about modern methods of diagnosis and treatment of AD.https://nnp.ima-press.net/nnp/article/view/2279alzheimer's diseasebiological markers of alzheimer's disease in cerebrospinal fluidhippocampal sclerosisanti-amyloid therapy |
| spellingShingle | K. V. Shevtsova D. O. Rozhkov D. A. Grishina V. V. Grinyuk V. V. Zakharov N. M. Kashakanova N. N. Koberskaya O. V. Kosivtsova A. B. Lokshina Yu. A. Starchina A. Yu. Tyurina A. Yu. Fedorova V. A. Parfenov Biological markers of Alzheimer's disease in cerebrospinal fluid: clinical and laboratory comparisons Неврология, нейропсихиатрия, психосоматика alzheimer's disease biological markers of alzheimer's disease in cerebrospinal fluid hippocampal sclerosis anti-amyloid therapy |
| title | Biological markers of Alzheimer's disease in cerebrospinal fluid: clinical and laboratory comparisons |
| title_full | Biological markers of Alzheimer's disease in cerebrospinal fluid: clinical and laboratory comparisons |
| title_fullStr | Biological markers of Alzheimer's disease in cerebrospinal fluid: clinical and laboratory comparisons |
| title_full_unstemmed | Biological markers of Alzheimer's disease in cerebrospinal fluid: clinical and laboratory comparisons |
| title_short | Biological markers of Alzheimer's disease in cerebrospinal fluid: clinical and laboratory comparisons |
| title_sort | biological markers of alzheimer s disease in cerebrospinal fluid clinical and laboratory comparisons |
| topic | alzheimer's disease biological markers of alzheimer's disease in cerebrospinal fluid hippocampal sclerosis anti-amyloid therapy |
| url | https://nnp.ima-press.net/nnp/article/view/2279 |
| work_keys_str_mv | AT kvshevtsova biologicalmarkersofalzheimersdiseaseincerebrospinalfluidclinicalandlaboratorycomparisons AT dorozhkov biologicalmarkersofalzheimersdiseaseincerebrospinalfluidclinicalandlaboratorycomparisons AT dagrishina biologicalmarkersofalzheimersdiseaseincerebrospinalfluidclinicalandlaboratorycomparisons AT vvgrinyuk biologicalmarkersofalzheimersdiseaseincerebrospinalfluidclinicalandlaboratorycomparisons AT vvzakharov biologicalmarkersofalzheimersdiseaseincerebrospinalfluidclinicalandlaboratorycomparisons AT nmkashakanova biologicalmarkersofalzheimersdiseaseincerebrospinalfluidclinicalandlaboratorycomparisons AT nnkoberskaya biologicalmarkersofalzheimersdiseaseincerebrospinalfluidclinicalandlaboratorycomparisons AT ovkosivtsova biologicalmarkersofalzheimersdiseaseincerebrospinalfluidclinicalandlaboratorycomparisons AT ablokshina biologicalmarkersofalzheimersdiseaseincerebrospinalfluidclinicalandlaboratorycomparisons AT yuastarchina biologicalmarkersofalzheimersdiseaseincerebrospinalfluidclinicalandlaboratorycomparisons AT ayutyurina biologicalmarkersofalzheimersdiseaseincerebrospinalfluidclinicalandlaboratorycomparisons AT ayufedorova biologicalmarkersofalzheimersdiseaseincerebrospinalfluidclinicalandlaboratorycomparisons AT vaparfenov biologicalmarkersofalzheimersdiseaseincerebrospinalfluidclinicalandlaboratorycomparisons |